At the forefront of PDGF research
Dr. Lynch is the world’s leading authority on growth factors, specifically PDGF research and commercialization. He has over 120 patents and over 150 published papers. Additionally, there is a body of work spanning over 1,000 published articles evaluating PDGF.
Explore the decades-long body of research to discover Dr. Lynch’s unmatched contribution to the advancement, innovation, and proliferation of PDGF in medicine and cosmetics.
DISCLAIMER: The accompanying articles discuss approved and unapproved uses of recombinant human Platelet-Derived Growth Factor-BB (rhPDGF-BB or PDGF). Unapproved uses of PDGF have not been approved by the FDA, and the safety and effectiveness of PDGF for such unapproved uses have not been established. The articles are provided for informational and scientific discussion purposes only and does not constitute promotion of any unapproved product or use.
PDGF Reviews
Published reviews of PDGF applications
- The Heritage of Platelet-Derived Growth Factor (Lynch SE, 2025) Modern Aesthetics; Nov 2025
- Pure Recombinant Platelet-Derived Growth Factor in Tissue Repair and Rejuvenation: A Review Exploring Frontiers in Regenerative Medicine (Younan SA, et al, 2025), DOI: 10.1097/PRS.0000000000012426
- Recombinant Human Platelet-Derived Growth Factor: Biology and Clinical Applications (Hollinger, et al, 2008) - PMID: 18292357
PDGF Science
Laboratory Research
- Comparative study of various growth factors and cytokines on type I collagen and hyaluronan production in human dermal fibroblasts (Kim, MS, et al, 2014) - PMID: 24641605
- Dermal fibroblasts have different extracellular matrix profiles induced by TGF‑β, PDGF and IL‑6 in a model for skin fibrosis (Juhl, et al, 2020) - PMID: 33057073
- Comprehensive Analysis of Chemotactic Factors for Bone Marrow Mesenchymal Stem Cells (Ozaki, et al, 2007) - PMID: 17348810
- Injury induces in vivo expression of platelet-derived growth factor (PDGF) and PDGF receptor mRNAs in skin epithelial cells and PDGF mRNA in connective tissue fibroblasts (Antoniades et al, 1991) - PMID: 1846446
rhPDGF-BB Safety and Toxicology Evaluations
Nonclinical and clinical safety
- Safety of Exogenous Recombinant Human Platelet-Derived Growth Factor-BB (rhPDGF-BB) for Medical and Cosmetic Applications: A Review. (Hee et al. 2026) - PMID: 41472395
- Safety of up to 140 Daily Applications of Recombinant Human Platelet-Derived Growth Factor (rhPDGF-BB) Onto Skin Wounds: Unboxing the Evidence. (Slade et al. 2025) - PMID: 41220237
- Safety of recombinant human platelet-derived growth factor-BB in Augment® Bone Graft (Solchaga et al, 2012) - PMID: 22511993
- Preclinical Toxicology Studies of Recombinant Human Platelet-Derived Growth Factor-BB Either Alone or in Combination with Beta-Tricalcium Phosphate and Type I Collagen (Young et al., 2010) - PMID: 21350649
- A review of nonclinical toxicology studies of becaplermin (rhPDGF-BB). (Knight et al, 1998) PMID: 9777973.
- Effect of implantation of Augment® Bone Graft on serum concentrations of platelet-derived growth factors: a pharmacokinetic study. (Solchaga et al, 2013) - PMID: 23334906.
- Clinical safety of becaplermin (rhPDGF-BB) gel. Becaplermin Studies Group. (Smiell, 1998) - PMID: 9777975.
Aesthetic Studies
Cosmetic topical clinical evaluations
Wound Healing Studies
Randomized, Controlled, Clinical Trials
- Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies (Smiell et al, 1999) - PMID: 10564562
- Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study (Rees et al, 1999) - PMID: 10417749
- Clinical Efficacy of Becaplermin (rhPDGF-BB) Gel (Wiemann et al, 1998) - PMID: 9777976
- Efficacy and Safely of a Topical Gel Formulation of Recombinant Human Platelet-Derived Growth Factor-BB (Becaplermin) in Patients With Chronic Neuropathic Diabetic Ulcers (Wiemann, et al, 1998) - PMID: 9589248
- Efficacy of topical recombinant human platelet-derived growth factor for treatment of diabetic lower-extremity ulcers: Systematic review and meta-analysis (Zhao et al, 2014) - PMID: 25060693
- A review of becaplermin gel in the treatment of diabetic neuropathic foot ulcers (Fang et al., 2008) - PMID: 19707423
Periodontal Studies
Randomized, Controlled, Clinical Trials
- Platelet-Derived Growth Factor Stimulates Bone Fill and Rate of Attachment Level Gain: Results of a Large Multicenter Randomized Controlled Trial (Nevins et al, 2005) - PMID: 16332231
- Histologic Evidence of Oral and Periodontal Regeneration Using Recombinant Human Platelet-Derived Growth Factor (Meghil et al, 2023) - PMID: 37109634
- Recombinant Human Platelet–Derived Growth Factor: A Systematic Review of Clinical Findings in Oral Regenerative Procedures (Tavelli et al, 2022) - PMID: 32392438
- Periodontal Regeneration in Humans Using Recombinant Human Platelet-Derived Growth Factor-BB (rhPDGF-BB) and Allogenic Bone (Nevins et al, 2003) - PMID: 14584860
Orthopaedic Studies
Randomized, Controlled, Clinical Trials
- Recombinant Human Platelet-Derived Growth Factor-BB and Beta-Tricalcium Phosphate (rhPDGF-BB/b-TCP): An Alternative to Autogenous Bone Graft (DiGiovanni et al, 2013) - PMID: 23824386
- The Impact of Patient Age on Foot and Ankle Arthrodesis Supplemented with Autograft or an Autograft Alternative (rhPDGF-BB/b-TCP) (Berlet, et al, 2020) - PMID: 33376929
- A Multicenter, Retrospective, Case Series of Patients with Charcot Neuroarthropathy Deformities Undergoing Arthrodesis Utilizing Recombinant Human Platelet-derived Growth Factor with Beta-Tricalcium Phosphate (Loveland, et al, 2021) - PMID: 33158722
- A retrospective review of recombinant human platelet-derived growth factor with beta-tricalcium phosphate bone graft substitute use in hindfoot and/or ankle arthrodesis (Loveland et al, 2023) - PMID: 37727282